Antiangiogenic therapies for high-grade glioma

CBTRUS: Statistical report: primary brain tumors in the United States, 2000–2004 (Central Brain Tumor Registry of the United States, 2008).

Wen, P. Y. & Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 359, 492–507 (2008).

Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).

Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009).

Prados, M. D. et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int. J. Radiat. Oncol. Biol. Phys. 23, 3–8 (1992).

Prados, M. D. et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int. J. Radiat. Oncol. Biol. Phys. 58, 1147–1152 (2004).

van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J. Clin. Oncol. 24, 2715–2722 (2006).

Wong, E. T. et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J. Clin. Oncol. 17, 2572–2578 (1999).

Yung, W. et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83, 588–593 (2000).

Yung, W. K. et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 17, 2762–2771 (1999).

Folkman, J. Angiogenesis. Annu. Rev. Med. 57, 1–18 (2006).

Ferrara, N. & Kerbel, R. Angiogenesis as a therapeutic target. Nature 438, 967–974 (2005).

Cloughesy, T. F. et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J. Clin. Oncol. 26 (May 20 Suppl.), abstract 2010b (2008).

Guiu, S. et al. Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study [French]. Rev. Neurol. (Paris) 164, 588–594 (2008).

Norden, A. D. et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70, 779–787 (2008).

Pope, W. B., Lai, A., Nghiemphu, P., Mischel, P. & Cloughesy, T. F. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66, 1258–1260 (2006).

Stark-Vance, V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract 342]. Neuro-Oncology 7, 369 (2005).

Vredenburgh, J. J. et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 13, 1253–1259 (2007).

Vredenburgh, J. J. et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25, 4722–4729 (2007).

Kreisl, T. N. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740–745 (2009).

Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83–95 (2007).

Jain, R. K. et al. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8, 610–622 (2007).

Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).

Plate, K., Breier, G., Weich, H. & Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845–848 (1992).

Stefanik, D. F., Rizkalla, L. R., Soi, A., Goldblatt, S. A. & Rizkalla, W. M. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res. 51, 5760–5765 (1991).

Reiss, Y., Machein, M. & Plate, K. The role of angiopoietins during angiogenesis in gliomas. Brain Pathol. 15, 311–317 (2005).

Shih, A. H. & Holland, E. C. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett. 232, 139–147 (2006).

Charalambous, C. et al. Interleukin-8 differentially regulates migration of tumor-associated and normal human brain endothelial cells. Cancer Res. 65, 10347–10354 (2005).

Du, R. et al. HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13, 206–220 (2008).

Schmidt, N. O. et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer 84, 10–18 (1999).

Millauer, B., Shawver, L. K., Plate, K. H., Risau, W. & Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576–579 (1994).

Soker, S., Fidder, H., Neufeld, G. & Klagsbrun, M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J. Biol. Chem. 271, 5761–5767 (1996).

Hu, B. et al. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 26, 5577–5586 (2007).

Holash, J. et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994–1998 (1999).

Oliner, J. et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6, 507–516 (2004).

Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 358, 2039–2049 (2008).

Noguera-Troise, I. et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444, 1032–1037 (2006).

Murdoch, C., Muthana, M., Coffelt, S. B. & Lewis, C. E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8, 618–631 (2008).

Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760 (2006).

Rich, J. N. Cancer stem cells in radiation resistance. Cancer Res. 67, 8980–8984 (2007).

Bao, S. et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66, 7843–7848 (2006).

Gilbertson, R. J. & Rich, J. N. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 7, 733–736 (2007).

Calabrese, C. et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69–82 (2007).

Folkins, C. et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 67, 3560–3564 (2007).

Eyler, C. E. & Rich, J. N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 26, 2839–2845 (2008).

Brada, M. et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 12, 259–266 (2001).

Brandes, A. A. et al. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann. Oncol. 12, 255–257 (2001).

Yung, W. K. et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83, 588–593 (2000).

Narayana, A. et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. 110, 173–180 (2009).

Nghiemphu, P. L. et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72, 1217–1222 (2009).

Poulsen, H. S. et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol. 48, 52–58 (2009).

Zuniga, R. M. et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol. 91, 329–336 (2009).

Wagner, S. A. et al. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. J. Clin. Oncol. 26 (May 20 Suppl.), abstract 2021 (2008).

Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. doi:10.1200/JCO.2008.19.8721.

FDA Briefing Document Oncology Drug Advisory Committee Meeting, March 31, 2009 [ online ] (2009).

Desjardins, A. et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin. Cancer Res. 14, 7068–7073 (2008).

Taillibert, S. et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 72, 1601–1606 (2009).

Duda, D. G., Jain, R. K. & Willett, C. G. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J. Clin. Oncol. 25, 4033–4042 (2007).

Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99, 11393–11398 (2002).

Wachsberger, P. R. et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 67, 1526–1537 (2007).

Zhang, F. et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc. Natl Acad. Sci. USA 106, 6152–6157 (2009).

Cao, Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal. 2, re1 (2009).

De Groot, J. F. et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601. J. Clin. Oncol. 26 (May 20 Suppl.), abstract 2020 (2008).

Zhou, Q., Guo, P. & Gallo, J. M. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin. Cancer Res. 14, 1540–1549 (2008).

De Groot, J. et al. A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J. Clin. Oncol. 27 (Suppl.), abstract 2047 (2009).

Sathornsumetee, S. et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol. 26, 271–278 (2008).

Sorensen, A. G. et al. A “vascular normalization” index as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 69, 5296–5300 (2009).

Chen, W. et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 25, 4714–4721 (2007).

Chen, W. et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J. Nucl. Med. 46, 945–952 (2005).

Pope, W. B. et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252, 182–189 (2009).

Guo, P. et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol. 162, 1083–1093 (2003).

Desjardins, A. et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J. Neurooncol. 83, 53–60 (2007).

Wen, P. Y. et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin. Cancer Res. 12, 4899–4907 (2006).

Bergers, G. & Benjamin, L. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401–410 (2003).

Martens, T. et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. 12, 6144–6152 (2006).

Li, X. et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res. 23, 2481–2487 (2003).

D'Amato, R., Loughnan, M., Flynn, E. & Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91, 4082–4085 (1994).

Fine, H. et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. 18, 708–715 (2000).

Marx, G. et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J. Neurooncol. 54, 31–38 (2001).

Fine, H. et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J. Clin. Oncol. 21, 2299–2304 (2003).

Chang, S. et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 60, 353–357 (2004).

Kesari, S. et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol. 10, 300–308 (2008).

Fine, H. A. et al. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin. Cancer Res. 13, 7101–7106 (2007).

Drappatz, J., Norden, A. D. & Wen, P. Y. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev. Neurother. 9, 519–534 (2009).

Brem, S. et al. Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol. 7, 246–253 (2005).

Mikkelsen, T. et al. Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. Invest. New Drugs 25, 259–263 (2007).

Browder, T. et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878–1886 (2000).

Samuel, D. P., Wen, P. Y. & Kieran, M. W. Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. Expert Opin. Investig. Drugs 18, 973–983 (2009).

Kesari, S. et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol. 9, 354–363 (2007).

Kieran, M. W. et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J. Pediatr. Hematol. Oncol. 27, 573–581 (2005).

Fine, H. A. et al. Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): a phase III study. J. Clin. Oncol. 26 (May 20 Suppl.), abstract 2005 (2008).

Reardon, D. et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103, 329–338 (2005).

Nabors, L. B. et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol. 25, 1651–1657 (2007).

Reardon, D. A. et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26, 5610–5617 (2008).

Stupp, R. et al. Mature results of a phase I/IIa trial of the integrin inhibitor cilengitide (EMD121974) added to standard concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma [abstract MA-10]. Society for Neuro-Oncology 12th Annual Scientific Meeting, Dallas, TX, USA (2007).

Avraamides, C. J., Garmy-Susini, B. & Varner, J. A. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 8, 604–617 (2008).

Horowitz, J. R. et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler. Thromb. Vasc. Biol. 17, 2793–2800 (1997).

Hood, J. D., Meininger, C. J., Ziche, M. & Granger, H. J. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. 274, H1054–H1058 (1998).

Fukumura, D. et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl Acad. Sci. USA 98, 2604–2609 (2001).

Eremina, V. et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129–1136 (2008).

Drappatz, J., Schiff, D., Kesari, S., Norden, A. D. & Wen, P. Y. Medical management of brain tumor patients. Neurol. Clin. 25, 1035–1071 (2007).

Norden, A. D. et al. Colon perforation during antiangiogenic therapy for malignant glioma. Neuro Oncol. 11, 92–95 (2009).

Vaughn, C., Zhang, L. & Schiff, D. Reversible posterior leukoencephalopathy syndrome in cancer. Curr. Oncol. Rep. 10, 86–91 (2008).

Shen, Q. et al. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science 304, 1338–1340 (2004).

Dietrich, J., Han, R., Yang, Y., Mayer-Proschel, M. & Noble, M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J. Biol. 5, 22 (2006).

Kunkel, P. et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 61, 6624–6628 (2001).

Lamszus, K., Kunkel, P. & Westphal, M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir. Suppl. 88, 169–177 (2003).

Rubenstein, J. L. et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2, 306–314 (2000).

Lucio-Eterovic, A. K., Piao, Y. & de Groot, J. F. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin. Cancer Res. 15, 4589–4599 (2009).

Chi, A. S., Norden, A. D. & Wen, P. Y. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics 6, 513–526 (2009).

Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220–231 (2009).

Fischer, I. et al. High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol. 10, 700–708 (2008).

Iwamoto, F. M. et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology (in press).

Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232–239 (2009).

Erber, R. et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18, 338–340 (2004).

Zagzag, D. et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab. Invest. 86, 1221–1232 (2006).

Rubin, J. B. et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl Acad. Sci. USA 100, 13513–13518 (2003).

Macdonald, D. R., Cascino, T. L., Schold, S. C. Jr, & Cairncross, J. G. Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277–1280 (1990).

Norden, A. D. et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J. Neurooncol. 92, 149–155 (2009).

Kamoun, W. S. et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol. 27, 2542–2552 (2009).

van den Bent, M. J. et al. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J. Clin. Oncol. 27, 2905–2908 (2009).

Mancuso, M. R. et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610–2621 (2006).

Quant, E. C. et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. doi:10.1215/15228517-2009-006.

Chang, S. M., Clarke, J. & Wen, P. Y. Novel imaging response assessment for drug therapies in recurrent malignant glioma. In American Society of Clinical Oncology 2009 Educational Book, 107–111 (American Society of Clinical Oncology, Alexandria, 2009).